Diagnos could sell its products in India
Sunday, September 8 2013 | 00 h 00 min | News
Diagnos, a corporation based in Brossard, Quebec, has signed a letter of intent with an Indian partner for the deployment of its tele-ophthalmology platform, CARA, in India.
The Computer Assisted Retinal Analysis (CARA) platform integrates with ophthalmic imaging hardware and software. CARA enhances retinal images in real time over the Internet.
Its partner in India, which for now remains anonymous, wishes to use Diagnos’ technology to slow down or halt the visual deterioration process that occurs in people with diabetes. The International Diabetes Federation estimates the number of diabetics in India to be more than 73 million, and this number could grow to 100 million by 2030. One patient out of nine will suffer from retinopathy and possibly lose their sight.
The initial mission would involve deploying mobile screening units, comprising the CARA platform and a qualified vision screening technician, to Mumbai and New Delhi. These units would also cover a radius of 500 km around the respective cities.
“The nature of the relationship offers the potential of scaling-up across the vast population and size of India,” said Peter Nowacki, Diagnos’ Vice-President – Healthcare. “We believe the lower cost dynamics in India coupled with a large volume potential across the country to be strong drivers of value for Diagnos shareholders.”